financials
Amgen raises 2016 outlook after Q1 earnings boost
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise
Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …
Cancer and immunology drugs drive strong Roche sales performance
July 23, 2015Sales and Marketing Roche, Severin Schwan, financials
Sales at Roche rose 6% in the first half of 2015, buoyed by “significant growth of sales and immunology medicines”, …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
J&J strong pharma sales can’t offset Q1 losses
April 15, 2015Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica
Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Roche sees Q3 sales rise
October 16, 2012Sales and Marketing Roche, financials
Roche’s sales for January to September this year were up 4% on the same nine-month period in 2011, with oncology …
IT problems at Swedish plant affect AstraZeneca
July 27, 2012Manufacturing and Production AstraZeneca, Nexium, Symbicort, financials
Software problems at a manufacturing facility operated by AstraZeneca in Sweden are having a material impact on the business, pegging …
